Profund Advisors LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,230 shares of the medical research company’s stock after acquiring an additional 824 shares during the period. Profund Advisors LLC’s holdings in Thermo Fisher Scientific were worth $3,648,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. Ilmarinen Mutual Pension Insurance Co purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $8,651,000. Psagot Investment House Ltd. purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $2,214,000. Voya Financial Advisors Inc. lifted its stake in Thermo Fisher Scientific by 3.0% in the 3rd quarter. Voya Financial Advisors Inc. now owns 7,064 shares of the medical research company’s stock valued at $2,030,000 after buying an additional 207 shares in the last quarter. Lowe Brockenbrough & Co. Inc. lifted its stake in Thermo Fisher Scientific by 0.5% in the 3rd quarter. Lowe Brockenbrough & Co. Inc. now owns 54,178 shares of the medical research company’s stock valued at $15,780,000 after buying an additional 292 shares in the last quarter. Finally, SWS Partners purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $377,000. Hedge funds and other institutional investors own 89.22% of the company’s stock.
A number of brokerages recently weighed in on TMO. Cowen reaffirmed an “outperform” rating and issued a $365.00 price target (up from $330.00) on shares of Thermo Fisher Scientific in a research note on Monday, January 6th. Credit Suisse Group began coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 22nd. They issued a “neutral” rating and a $341.00 price target on the stock. Needham & Company LLC raised their price target on shares of Thermo Fisher Scientific from $331.00 to $341.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Argus reaffirmed a “positive” rating and issued a $370.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, February 24th. Finally, Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $340.00 to $341.00 and gave the company an “outperform” rating in a research note on Wednesday, March 4th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $340.29.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $3.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.54 by $0.01. Thermo Fisher Scientific had a net margin of 14.47% and a return on equity of 17.24%. The firm had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.78 billion. During the same quarter in the previous year, the company earned $3.25 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 13.59 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, April 16th. Investors of record on Monday, March 16th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.31%. The ex-dividend date is Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.19. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.13%.
In related news, Director Jim P. Manzi sold 4,410 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $332.32, for a total value of $1,465,531.20. Following the completion of the sale, the director now owns 21,632 shares in the company, valued at approximately $7,188,746.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.45% of the stock is currently owned by company insiders.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: Cost of Capital
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.